全文获取类型
收费全文 | 7466篇 |
免费 | 607篇 |
国内免费 | 113篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 126篇 |
妇产科学 | 102篇 |
基础医学 | 298篇 |
口腔科学 | 39篇 |
临床医学 | 803篇 |
内科学 | 791篇 |
皮肤病学 | 66篇 |
神经病学 | 300篇 |
特种医学 | 134篇 |
外科学 | 537篇 |
综合类 | 988篇 |
预防医学 | 1708篇 |
眼科学 | 71篇 |
药学 | 1599篇 |
8篇 | |
中国医学 | 257篇 |
肿瘤学 | 331篇 |
出版年
2024年 | 5篇 |
2023年 | 164篇 |
2022年 | 366篇 |
2021年 | 482篇 |
2020年 | 480篇 |
2019年 | 384篇 |
2018年 | 358篇 |
2017年 | 362篇 |
2016年 | 383篇 |
2015年 | 341篇 |
2014年 | 822篇 |
2013年 | 690篇 |
2012年 | 540篇 |
2011年 | 559篇 |
2010年 | 450篇 |
2009年 | 365篇 |
2008年 | 270篇 |
2007年 | 256篇 |
2006年 | 200篇 |
2005年 | 122篇 |
2004年 | 113篇 |
2003年 | 108篇 |
2002年 | 64篇 |
2001年 | 47篇 |
2000年 | 46篇 |
1999年 | 31篇 |
1998年 | 16篇 |
1997年 | 23篇 |
1996年 | 15篇 |
1995年 | 13篇 |
1994年 | 12篇 |
1993年 | 10篇 |
1992年 | 12篇 |
1991年 | 8篇 |
1990年 | 8篇 |
1989年 | 8篇 |
1988年 | 2篇 |
1987年 | 3篇 |
1986年 | 6篇 |
1985年 | 9篇 |
1984年 | 6篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1979年 | 5篇 |
1978年 | 2篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1974年 | 5篇 |
排序方式: 共有8186条查询结果,搜索用时 93 毫秒
101.
目的 研究大鼠灌胃给予驱白巴布期片13周重复给药的毒性。方法 选取SD大鼠120只,雌雄各半,分为溶媒对照组及驱白巴布期片1.5、3.0、6.0 g·kg-1 3个剂量组,每天给药1次,给药容积为10 mL·kg-1,连续给药13周,停药恢复4周。试验期间,每天进行一般状态观察,给药期及恢复期每周测定1次体重,给药结束取20只和恢复期结束取10只动物安乐死,进行血液学、血液生化学、脏器系数和病理组织学检查。结果 驱白巴布期片灌胃给药13周后,大鼠一般状态正常、血液学和血液生化学等指标与溶媒对照组相比无显著性差异(P>0.05),大鼠主要脏器系数均在正常范围内,病理组织学检查未见明显异常。结论 驱白巴布期片≤6 g·kg-1剂量下灌胃给予大鼠未见明显毒性反应,其最大无毒反应剂量(NOAEL)≥6 g·kg-1。 相似文献
102.
103.
《Vaccine》2018,36(16):2126-2132
IntroductionHigh rate of influenza infection in children made influenza vaccination strongly recommended for all person aged >6 months in Indonesia. Bio Farma Trivalent Influenza HA (Flubio®) vaccine has been used in adolescents and adults, resulted in increased seroconversion, seroprotection rates and geometric mean titer (GMT). However, no data is available regarding its efficacy and safety in children. This study aimed to assess the immunogenicity and safety of Flubio® vaccine in infants and children.Materials and methodsThis was a phase II, open-labeled, clinical trial conducted on healthy children aged 6 month-11 years, vaccinated with 1 or 2 doses of Influenza HA vaccine, with a 28-day interval. Flubio® vaccine composed of A/California/7/2009 (H1N1) pandemic 09, A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 strain. This study was held at East Jakarta, Indonesia from May until July 2014. A Total of 405 subjects were included and divided into three groups: A(6–35 months), B(3–8 years), and C(9–11 years). Antibody titer was measured at visit V1 (Day 0), V2 (28 days/+7days after the first dose) and V3 (28 days/+7days after second dose). The seroprotection and seroconversion rates were assessed. Safety was assessed up to 28 days following each dose.ResultsA total of 404 subjects completed the study. After vaccination, all subjects achieved seroprotection and increased seroconversion rates, with post-vaccination antibody titer of ≥1:40 HI for all strains. The GMT also increased significantly. Within 30 min after vaccination, 14.6% and 2% had local and systemic reactions; meanwhile, between 30 min to 72 h after vaccination, 35.1% and 13.6% subjects had local and systemic reactions, respectively. Most reactions were mild. No serious adverse event (SAE) was reported related to vaccine.ConclusionFlubio® (Influenza HA Trivalent) vaccine is immunogenic and safe for children aged 6 months-11 years.Trial Registration: The trial is registered at the US National Institutes of Health (ClinicalTrials.gov) #NCT02093260. 相似文献
104.
《Vaccine》2018,36(21):2968-2972
BackgroundJapan licensed the conjugate Haemophilus influenzae type b vaccine, Vaxem™ Hib, based on clinical studies using subcutaneous injection. The present study was performed to ensure this vaccine is suitable for intramuscular injection in Japanese children.MethodsThirty-one healthy 2–6-month-old infants received three doses of Vaxem™ Hib by intramuscular injection at 4-week intervals and a booster dose 1 year later, concomitant with routine infant (DTaP-IPV and pneumococcal) and toddler (measles–rubella) vaccines. Immunogenicity was assessed before and after the primary series and booster dose by enzyme-linked immunosorbent assay for anti-polyribosyl-ribitol-phosphate (PRP) antibodies. Safety was assessed by medical examination and diary cards completed by the subjects’ parents/legal guardians.ResultsThere were no vaccine-related serious adverse events or withdrawals; all children completed the study. Four weeks after the primary series, the geometric mean anti-PRP titer (GMT) was 19.68 μg/mL, and all children had seroprotective titers (≥0.15 μg/mL) that persisted until the booster dose. Proportions of titers indicative of long-term protection (≥1.0 μg/mL) were 100% after the primary series and 77.4% before the booster. Anamnestic responses to the booster had a GMT of 51.33 μg/mL, and 100% had titers ≥1.0 μg/mL. All but one subject reported injection site reactions as resolved within 3 days of vaccination; systemic reactions due to Hib and routine vaccines were also resolved within this period.ConclusionsVaxem™ Hib was generally well tolerated and immunogenic in Japanese children when administered by intramuscular injection in a three-dose primary series and as a booster with concomitant routine vaccines.Clinical trial registry: Registered on Clinical Trials.gov: NCT02074345. 相似文献
105.
Evaluating the readability and suitability of construction occupational safety and health materials designed for workers 下载免费PDF全文
Clayton Sinyai PhD Brenda MacArthur PhD Thomas Roccotagliata MA 《American journal of industrial medicine》2018,61(10):842-848
Introduction
Printed materials for training and hazard communication are an essential part of occupational safety and health programs, but must be understood by their intended audience.Methods
Researchers collected 103 safety training handouts, brochures, and Safety Data Sheets and scored them for readability and suitability using four standard health communication instruments: the SMOG test, the Flesch‐Kincaid Reading Ease Assessment, the SAM (Suitability Assessment of Materials), and CCI (the CDC Clear Communication Index).Results
Some of the materials used unfamiliar and technical terms. The SAM and CCI checklists revealed several elements of design and layout known to facilitate communication and comprehension, but missing from most of the materials scored.Conclusion
Occupational safety and health professionals preparing curricula and handouts for distribution to workers should incorporate some form of readability and suitability assessment to help ensure their written materials are clear and comprehensible to all segments of their audience.106.
《Vaccine》2018,36(29):4278-4286
BackgroundThis study evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) when the first dose was co-administered with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults aged ≥50 years.MethodsIn this open label, multi-center study (NCT02045836), participants were randomized 1:1 to receive either the first dose of RZV and PPSV23, co-administered at Day 0 and the second dose of RZV at Month 2 (Co-Ad group), or PPSV23 at Day 0, the first dose of RZV at Month 2 and second dose of RZV at Month 4 (Control group). Co-primary objectives were the RZV vaccine response rate (VRR) in the Co-Ad group and the non-inferiority of the antibody responses to RZV and PPSV23 in the Co-Ad group compared to the Control group. Reactogenicity and safety were also assessed.Results865 participants were vaccinated (Co-Ad: 432, Control: 433). VRRs to RZV were >98% in both groups. Humoral immune responses to co-administration of RZV and PPSV23 were non-inferior to sequential administration. All three co-primary immunogenicity objectives were met. Solicited local symptoms after the first RZV dose were reported by similar percentages of participants in both groups. Solicited general symptoms were more frequently reported when the first dose of RZV and PPSV23 were co-administered. No differences were apparent between groups after the second RZV dose.ConclusionsNo immunologic interference was observed between RZV and PPSV23 when co-administered in adults ≥50 years. No safety concerns were raised. 相似文献
107.
《Vaccine》2018,36(3):347-354
New vaccines designed to prevent diseases endemic in low and middle-income countries (LMICs) are now being introduced without prior record of utilization in countries with robust pharmacovigilance systems. To address this deficit, our objective was to demonstrate feasibility of an international hospital-based network for the assessment of potential epidemiological associations between serious and rare adverse events and vaccines in any setting. This was done through a proof-of-concept evaluation of the risk of immune thrombocytopenic purpura (ITP) and aseptic meningitis (AM) following administration of the first dose of measles-mumps-containing vaccines using the self-controlled risk interval method in the primary analysis. The World Health Organization (WHO) selected 26 sentinel sites (49 hospitals) distributed in 16 countries of the six WHO regions. Incidence rate ratios (IRR) of 5.0 (95% CI: 2.5–9.7) for ITP following first dose of measles-containing vaccinations, and of 10.9 (95% CI: 4.2–27.8) for AM following mumps-containing vaccinations were found. The strain-specific analyses showed significantly elevated ITP risk for measles vaccines containing Schwarz (IRR: 20.7; 95% CI: 2.7–157.6), Edmonston-Zagreb (IRR: 11.1; 95% CI: 1.4–90.3), and Enders’Edmonston (IRR: 8.5; 95% CI: 1.9–38.1) strains. A significantly elevated AM risk for vaccines containing the Leningrad-Zagreb mumps strain (IRR: 10.8; 95% CI: 1.3–87.4) was also found. This proof-of-concept study has shown, for the first time, that an international hospital-based network for the investigation of rare vaccine adverse events, using common standardized procedures and with high participation of LMICs, is feasible, can produce reliable results, and has the potential to characterize differences in risk between vaccine strains. The completion of this network by adding large reference hospitals, particularly from tropical countries, and the systematic WHO-led implementation of this approach, should permit the rapid post-marketing evaluation of safety signals for serious and rare adverse events for new and existing vaccines in all settings, including LMICs. 相似文献
108.
《Vaccine》2018,36(5):698-706
BackgroundTo support vaccination programs in developing countries, a 4-dose vial presentation of pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was developed. This study assessed immunologic non-inferiority and safety of the investigational PHiD-CV 4-dose versus licensed 1-dose vial presentation in infants.MethodsIn this phase III, mono-center, observer-blind study in Bangladesh, 6–10-week-old infants were randomized 1:1 to receive PHiD-CV primary vaccination (at ages 6, 10, 18 weeks) and a booster dose (at age 9 months) with a 4-dose vial (with preservative, 4DV group) or 1-dose vial (preservative-free, 1DV group). DTPw-HBV/Hib was (co)-administered per study protocol and polio, measles and rubella vaccines as part of the national immunization program. Non-inferiority of PHiD-CV 4-dose versus 1-dose vial for each vaccine pneumococcal serotype (VT) and vaccine-related serotype 19A in terms of antibody geometric mean concentration (GMC) was assessed (criterion: upper limit of 2-sided 95% confidence interval of antibody GMC ratios [1DV/4DV] <2-fold). Immune responses were measured. Solicited, unsolicited and serious adverse events (AEs) were evaluated.ResultsOf 320 infants (160 per group) vaccinated during the primary vaccination phase, 297 received a booster. Non-inferiority was demonstrated for each VT and 19A. One month post-primary vaccination, for most VT, ≥97.9% of infants in each group had antibody concentrations ≥0.2 μg/mL; for 19A ≥ 80.1% reached this threshold. Pneumococcal antibody responses and opsonophagocytic activity for each VT and 19A were within similar ranges between groups after primary and booster vaccination, as were anti-protein D responses. Booster immune responses were observed in both groups. Reported AEs were within similar ranges for both presentations.ConclusionImmunologic non-inferiority of PHiD-CV 4-dose vial (with preservative) versus PHiD-CV 1-dose vial (preservative-free) was demonstrated. Immune responses and reactogenicity following primary/booster vaccination were within similar ranges for both presentations. PHiD-CV 4-dose vial would help improve access and coverage in resource-limited countries.Clinical Trial Registry: NCT02447432. 相似文献
109.
Priv.-Doz. Dr. Arndt Klocke J?rn Kemper Dirk Schulze Gerhard Adam B?rbel Kahl-Nieke 《Journal of orofacial orthopedics》2005,66(4):279-287
AbstractBackground: Orthodontic appliances pose a potential risk during magnetic resonance imaging (MRI) due to forces on metallic objects within the static magnetic field of MRI systems. The aim of the present investigation was to measure forces on orthodontic wires caused by the static magnetic field of a 1.5-Tesla MRI system, and to assess the safety hazards associated with these forces.Materials and Methods: Thirty-two different orthodontic wires (21 arch wires, eight ligature wires and three retainer wires) were investigated in a 1.5-Tesla MRI system (Magnetom Symphony, Siemens Medical Solutions, Erlangen, Germany). The translational forces were measured using the deflection angle test (ASTM F2052-02); rotational forces were assessed on a 5-point qualitative scale.Results and Conclusion: All retainer wires and the steel arch wires (the Noninium® arch wire being the exception) were subjected to considerable rotational and translational forces within the MRI system’s magnetic field. Translational forces were from 9.1- to 27.6-times as high as gravitational forces on these objects. Steel ligature wires and arch wires made of cobalt chromium, titanium molybdenum, nickel-titanium, and brass alloys showed no or negligible forces within the magnetic field. The translational and rotational forces within the MRI magnetic field should pose no risk to carefully-ligated arch wires. Steel retainer wire bonds should be checked to ensure secure attachment prior to an MRI investigation.* both authors share first authorship 相似文献
110.
【摘要】 目的 探讨插入型肠梗阻导管对妊娠期单纯性肠梗阻的疗效及母婴预后的影响。 方法 选择2018年2月~2019年8月我院收治的36例妊娠期单纯性肠梗阻患者,按随机数表法分为观察组和对照组,每组各18例。在常规处理基础上,对照组给予常规留置鼻胃管进行胃肠减压,观察组给予插入型肠梗阻导管进行胃肠减压。比较两组治疗24 h临床疗效、临床指标及母婴结局。 结果 两组患者治疗24 h临床疗效差异无统计学意义(P>0.05);观察组置管24 h引流量明显高于对照组,腹痛消失时间、肛门排气时间、排便时间及住院时间均明显比对照组短(均P<0.05);观察组有14例(77.78%)患者治疗康复出院,对照组10例(55.56%)患者治疗康复出院,差异无统计学意义(P>0.05)。 结论 和传统留置鼻胃管相比,插入型肠梗阻导管可更有效缩短妊娠期单纯性肠梗阻患者症状缓解时间及住院时间,提高引流量,但临床上仍需综合考虑患者个体情况,选择最有效的治疗,确保母婴安全。 相似文献